about
Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after deliveryA global approach to the management of EMR (electronic medical records) of patients with HIV/AIDS in sub-Saharan Africa: the experience of DREAM softwareImproving HIV-2 detection by a combination of serological and nucleic acid amplification test assays.Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique.Viral sequence analysis of HIV-positive women and their infected children: insight on the timing of infection and on the transmission network.The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.Ebola virus disease 2013-2014 outbreak in west Africa: an analysis of the epidemic spread and response.Nutritional rehabilitation of HIV-exposed infants in Malawi: results from the drug resources enhancement against AIDS and malnutrition programExtended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV.Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa.Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding.Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibilityHepatitis E virus infection in HIV-infected pregnant women and their children in Malawi.New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.Weight changes during and after 6 months of breastfeeding in HIV-infected mothers receiving antiretroviral therapy in Malawi.Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique.Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique.Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique.Hepatitis in Albanian children: molecular analysis of hepatitis A virus isolates.Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district levelSubtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.Nucleotide correlation between HAV isolates from human patients and environmental samples.Surveillance of infections in hospital: agents and antibiotic-resistance.Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique.A large infantile gastroenteritis outbreak in Albania caused by multiple emerging rotavirus genotypes.
P50
Q28534751-A5A1DBD6-F79F-43D9-A229-5B9B1315978CQ28751344-ECEBF0C5-69D6-49A2-B64F-06D4DE8D85F3Q34046466-2F6CB8D2-087C-48B7-BF13-164C470FE5F7Q34240160-8E1AA8CF-52A2-4630-B502-F6F2160B6734Q34266269-0E7731FC-1D3A-4B19-A01D-E770DE1E41FBQ34523530-8B3AB998-EA59-4F51-8DFA-D1DF7930C16CQ35234172-3129A3B7-D9CD-4890-8228-7CEC9765392AQ35860439-60EB4C15-0A27-4A2C-AD48-B2A732B0E28BQ37889592-4A9DD8CA-8F51-4DF9-9255-CBE88A59900BQ38394525-6969C114-7B4F-4013-8849-A472D2575AC8Q38410459-D5203BB4-9657-416D-A0C6-8437757A7CD8Q38452483-6EB1A841-80FD-428C-ACAD-0868615245DFQ38966133-09F5AD00-5184-42CE-9887-1F4B50827005Q39213753-7BC58188-22B4-4D63-B4AC-9943A9C30CCBQ39213760-53AF5FAB-CAB0-4E68-8D70-AFE28AEF5539Q39335189-19A48917-D98A-4AC6-B809-9A5CAB74E9E8Q39555733-9380B4DB-1623-4BE3-83E6-C244CDE8F5D6Q40251666-55E3E647-0EE5-46A8-87C6-E963DE7C6608Q41702637-0D7DD871-4F60-422C-99B9-24886531E473Q41760045-371C3FA1-46BF-4466-A557-40FCF585DD89Q42872394-E51B335B-DC4D-4BE7-B901-198A4441EA6EQ43049052-D02CA1FF-12CC-42A8-AFDD-3A498ED43951Q43217465-C6B03E79-A20C-454E-BE79-6428E3F6BE44Q43482078-79A03F13-756F-4F5E-BE14-2BB0FA3F5066Q43649738-60B20F33-72B8-4D99-8A8C-14298DC8A3E5Q43811493-D37342DA-5ECF-4C5B-BECE-4C48540D5BC7Q44237932-C32FBA73-6B9E-44F4-B43F-39FC8436FEF0Q44444294-B905D642-3BDE-4F68-8B8F-7F3EBE8B6AD9Q44495122-2FA803CE-DA55-4384-8020-8BEC518FF5B3Q44775285-CCC24521-F541-427F-BD76-27194F8F1537Q44799271-76A51243-CA83-4CDC-A161-F261B0D68A31Q45017203-94E1C20E-F27D-4FF7-9B3C-B33800F6B02AQ45150537-9EC84C63-3D0F-4B57-888D-BE962F8C763CQ45176842-B3D23987-72F8-4FC2-AD39-369FFBA9F871Q45355192-183B4B22-31B2-4B03-B9C4-72F037A1127CQ46051781-CF07EDF8-5DCD-41D9-8668-AAA14967D900Q46790897-0675A053-803B-479E-8928-8B4E09DAD9BBQ46808222-B356BCAE-35B9-4C30-8B0F-C7CDB039CB72Q46813664-EE94631A-F3AE-4478-8700-3B6B275AA906Q51713038-15B8AE1C-F45E-4727-A23C-2FEF3F82FD40
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Leonardo Palombi
@ast
Leonardo Palombi
@en
Leonardo Palombi
@es
Leonardo Palombi
@nl
Leonardo Palombi
@sl
type
label
Leonardo Palombi
@ast
Leonardo Palombi
@en
Leonardo Palombi
@es
Leonardo Palombi
@nl
Leonardo Palombi
@sl
prefLabel
Leonardo Palombi
@ast
Leonardo Palombi
@en
Leonardo Palombi
@es
Leonardo Palombi
@nl
Leonardo Palombi
@sl
P106
P1153
7006403318
P21
P214
27148207554100340340
P31
P396
IT\ICCU\TO0V\036034
P496
0000-0003-1806-5278
P735
P7859
viaf-27148207554100340340